Xeris Biopharma Holdings Inc
2B30
Company Profile
Business description
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Contact
1375 West Fulton Street
Suite 1300
ChicagoIL60607
USAT: +1 844 445-5704
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
394
Stocks News & Analysis
stocks
Weekly Earnings Wrap: CBA, CSL, MQG and more
Everything you need to know on last weeks earnings results
stocks
ASX player rallies on small guidance upgrade
Our fair value is maintained despite investor enthusiasm.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With strong fourth-quarter earnings and AI integration, here’s what we think of Alphabet stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,142.00 | 63.40 | -0.69% |
| CAC 40 | 8,340.56 | 27.32 | 0.33% |
| DAX 40 | 24,852.69 | 3.46 | -0.01% |
| Dow JONES (US) | 49,451.98 | 669.42 | -1.34% |
| FTSE 100 | 10,402.44 | 69.67 | -0.67% |
| HKSE | 26,523.07 | 509.47 | -1.88% |
| NASDAQ | 22,597.15 | 469.32 | -2.03% |
| Nikkei 225 | 57,268.49 | 371.35 | -0.64% |
| NZX 50 Index | 13,198.18 | 333.30 | -2.46% |
| S&P 500 | 6,832.76 | 108.71 | -1.57% |
| S&P/ASX 200 | 8,920.40 | 52.50 | -0.59% |
| SSE Composite Index | 4,109.19 | 24.82 | -0.60% |